Text Size

A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

This study has been completed.
Sponsor:
Collaborator:
Chinese Academy of Sciences
Information provided by:
Kunming Medical University
ClinicalTrials.gov Identifier:
NCT00703742
First received: June 20, 2008
Last updated: June 24, 2011
Last verified: June 2011
History of Changes
  Purpose

The purpose of this study is:

  1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
  2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
  3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
  4. to find possible predispose to MDD
  5. to explore the DNA methylation status in depression;

Condition Intervention
Depression
Depression Secondary to Other Disease
 Drug: Escitalopram

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Health Services Research
Official Title: A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Kunming Medical University:

Primary Outcome Measures:
  • change of fMRI after medication [ Time Frame: baseline, 4 weeks, 8 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: June 2008
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A,1
A: Escitalopram, 20 mg/day,8weeks
 Drug: Escitalopram
A,1: Escitalopram, oral, 20 mg/day, 8 weeks

Detailed Description:
  1. to explore the pathology of depression
  2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
  3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • DSM-IV Major Depression or Dysthymia
  • Age 18-65
  • Physically healthy
  • Drug-free

Exclusion Criteria:

  • Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
  • History of Psychosis or Epilepsy
  • Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
  • Bipolar I
  • Need for wash-out from effective treatment in order to participate
  • Pregnant
  • High suicide risk
  • Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00703742

Locations
China, Yunnan
The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China, 650031
Sponsors and Collaborators
Kunming Medical University
Chinese Academy of Sciences
Investigators
Study Director: Xu Xiufeng Kunming Medical University
  More Information

No publications provided by Kunming Medical University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Kunming Medical College
ClinicalTrials.gov Identifier: NCT00703742     History of Changes
Other Study ID Numbers: Kunming MC
Study First Received: June 20, 2008
Last Updated: June 24, 2011
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Antidepressive Agents
Citalopram
Dexetimide
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antiparkinson Agents
Anti-Dyskinesia Agents
 Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Serotonin Agents

ClinicalTrials.gov processed this record on June 17, 2013